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Resolution of lupus-related left ventricular wall thickening and interstitial 
lung disease in a child with pulsed steroids and cyclophosphamide 
 
INTRODUCTION 
The most common form of cardiac involvement in 
pediatric patients with systemic lupus 
erythematosus (pSLE) is pericardiatis with 
pericardial effusion, and less commonly, endo-or 
myocarditis or valvular disease1. Clinical or 
subclinical pleuropulmonary disease is also a 
frequent manifestation of childhood SLE2. The 
clinical spectrum includes pleuritis, pneumonitis, 
infectious pneumonia, pulmonary hemorrhage, 
pulmonary hypertension and pneumothorax. 
Uncommon manifestations are diaphragmatic 
involvement, vasculitis, and pulmonary embolism1. 
Diffuse interstitial lung disease occurs occasionally 
in pSLE3. However, pulmonary involvement was 
found frequent among a group of Egyptian children 
with SLE and tended to correlate with disease 
severity4. We describe a female child with SLE who 
developed left ventricular hypertrophy and 
interstitial lung disease that resolved completely 




A twelve-year-old female patient of 
consanguineous parents presented to the emergency 
room of the Children’s Hospital, Ain Shams 
University complaining of high remittent fever and 
bilateral lower limbs swelling of gradual onset and 
one week duration. The parents reported that their 
child’s illness started one month ago with bouts of 
unexplained high fever, malaise, decreased appetite 
and weight loss. Shortly after, a non-itchy 
erythematous rash appeared on her nose and cheeks 
with exacerbation on sun exposure with painful 
swelling of both knees and ankles; her condition 
was poorly responding to repeated doses of 
antipyretics and analgesics. 
On admission, physical examination revealed 
that the patient was feverish (38.5°C), had a malar 
rash, she was tachycardiac (HR: 120/min) and 
dyspneic (RR: 40/min), her blood pressure was 
normal (110/60mmHg). There was no jugular 
venous congestion or hepatomegaly. Cardiac and 
chest examination were free.  Patient had arthritis of 
Case report 
Cardiopulmonary involvement is one of the important manifestations of 
systemic lupus erythematosus (SLE) that tends to be more common in adults 
than children with SLE. SLE-related cardiopulmonary affection ranges from 
subclinical to life threatening condition. Although increased left ventricular 
mass and interstitial lung disease have been reported in association with 
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hypertrophy with preserved systolic function, electrocardiogram showed 
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both knees and ankles together with   bilateral lower 
limb edema up to the knees. Her laboratory 
evaluation revealed normal leukocytic count (8.8x 
109/L), mild normocytic normochromic anemia (9.2 
gm/dl), normal platelet count (301x109/L), an 
elevated erythrocyte sedimentation rate (100 
mm/hr), hypoalbuminemia (2.6 gm/dl)  and  normal 
renal functions (blood urea nitrogen: 18 and serum 
creatinine: 0.3 mg/dl). Her thyroid profile was 
normal.  Urine analysis showed albuminuria (+3 by 
dipsticks), hematuria (>100/HPF), pyuria (20-
25/HPF) and granular casts, the urine culture was 
negative. The 24-hour urinary proteins was 1.5 
grams/24 hours. Immunological studies showed 
positive ANA (titer: 1/640, homogenous pattern), 
anti-ds DNA was positive (400 IU/ml) with 
consumed C3 and C4 (27mg/dl and 7mg/dl 
respectively).  Both lupus anti-coagulant and anti-
cardiolipin antibodies were negative.  Renal biopsy 
revealed lupus nephritis class III (focal proliferative 
glomerulonephritis). Thus, our patient was a case of 
SLE and lupus nephritis. She was placed on full 
dose steroids (60 mg/day) and started monthly 
cyclophosphamide at a dose of 500 mg/m2. Four 
days after starting steroids, her cardiac evaluation 
included 12 lead electrocardiogram  revealing sinus 
tachycardia, an echocardiography showing 
increased  left ventricular wall thickening (LVWT) 
with preserved systolic function (ejection fraction: 
67%) and mild pericardial effusion  (figure1a). A 
24-hour-ambulatory Holter monitoring showed 
sinus tachycardia and infrequent premature 
ventricular contractions. 
While on full dose steroids, patient developed 
in addition to the persistent dyspnea, frequent non-
productive cough, her chest examination revealed 
only few bibasilar fine crepitations. So evaluation 
of pulmonary involvement was carried out showing 
pulmonary infiltrates on plain chest x-ray, sputum 
and blood cultures were both negative for 
organisms. Pulmonary function tests   showed mild 
restrictive pattern and high resolution computed 
tomography (HRCT) of the chest  revealed  veiling 
of both lungs with increased attenuation and 
interstitial nodules with bilateral mild pleural 
effusion (figure 2a). 
In view of the marked nephrosis that was not 
responding adequately to oral steroids and pulsed 
monthly cyclophosphamide, and the 
cardiopulmonary involvement, monthly methyl 
prednisolone (30mg/kg maximum1gm) was added. 
An angiotensin receptor blocker and diuretics were 
added to control the newly developed hypertension 
(140/90 mmHg) and edema. Her condition 
gradually improved concerning renal and cardio-
pulmonary involvement. At 3-months follow-up, 
the patient had no constitutional symptoms with 
resolution of dyspnea and tachycardia, her 
laboratory evaluation showed normalization of C3 
and C4 and negative anti-ds DNA with marked 
decrease in proteinuria.  
A follow up echocardiography was done and it 
revealed normalization of LVWT (figure 1b). A 
pulmonary function tests become normal on follow 
up, with the resolution of HRCT scan findings of 
the chest (figure 2b). 
So, cardiopulmonary affection was one of the 
presenting manifestations in this patient with SLE 
that resolved completely 3 months after aggressive 






Figure 1. Echocardiography (long axis parasternal view) of the patient showing: a- 
Left ventricular hypertrophy with no chamber dilatation at presentation, b- Resolution 
of the left ventricular hypertrophy  3 months after immunosuppressive therapy. 
    




Figure 2. High resolution computed tomography (HRCT) of the chest showing: a- Veiling of 
both lungs with increased attenuation and interstitial nodules at presentation, b- Clear both 




Cardiovascular involvement is the third most 
common reason of death in patients with SLE5. 
Prevalence of clinical heart disease among SLE 
children ranges from 32 to 68 %6. Subclinical 
disease as demonstrated by echocardiography and 
autopsy studies are also common7. 
Our patient was a previously healthy 12 years 
old girl who presented acutely with features 
consistent with SLE. The only clinical 
cardiovascular finding  was tachycardia out of 
proportion to fever, Echocardiographic examination 
revealed increased LVWT with preserved systolic 
function (ejection fraction was 68%) and chamber 
size with minimal pericardial effusion. Alterations 
in left ventricular (LV) structure and function have 
been reported among the cardiac manifestations of 
SLE in adults8. A direct disease related effect of 
SLE on LV structure has been suggested9. 
LVWT become normal within three months, 
making this finding a transitional one not consistent 
with myocardial hypertrophy. Transient LVWT has 
been described in a child with SLE and myositis10. 
Since the patient’s echocardiography showed 
no ventricular dilatation or dysfunction, these 
findings were considered atypical for myocarditis. 
LVWT in SLE may therefore be due to direct 
myocardial involvement as both fibrinoid and 
cellular infiltration and increased myocardial 
fibrous tissue are seen in SLE11. 
Chronic interstitial lung disease characterized 
by chronic nonproductive cough, recurrent pleuritic 
chest pain, and dyspnea on exertion have been 
reported children and adults with SLE12,13.  Physical 
examination may show fever, cyanosis, and 
bibasilar crackles. Clubbing is less common in SLE 
than in idiopathic ILD14.  HRCT   findings   in SLE-
induced ILD include interlobular and intralobular 
septal thickening, air-space nodules, and 
architectural distortion15. This is in addition to 
pulmonary function test abnormalities. Restrictive 
pattern of pulmonary function tests was reported in 
62% of children with SLE with the most frequent 
HRCT findings were ground glass appearance, 
pleural irregularity, bronchial wall thickening and 
pulmonary nodules4.  
Bronchoalveolar lavage (BAL) is considered to 
be an effective and relatively safe method of 
obtaining inflammatory cells and secretions in 
patients with pulmonary disease where lymphocyte 
predominance was found in symptomatic patients 
while both lymphocytes and neutrophils infiltrates 
exist in those with only radiographic changes of 
ILD16. Although diagnosis of primary lung disease 
may only be made by lung biopsy, with appropriate 
microbiological and histopathological 
investigation15. Our patient had no clinical or 
laboratory evidence of infective pulmonary disease, 
the HRCT finding of the chest and the restrictive 
pattern of the pulmonary function tests suggested 
SLE-related interstitial lung disease.    
Our patient’s chest condition   represented an 
initial stage of   insidious onset of SLE-induced 
interstitial lung disease which might progress to 
more severe form if inadequately treated.  High-
dose corticosteroids is the mainstay of treatment for 
diffuse ILD; although other agents such as 
cyclophosphamide, azathioprine, intravenous 
gamma globulin, and plasmapheresis have been 
used with varying degrees of success16.  Previous 
studies on the pleuropulmonary manifestations of 
pSLE reported the occurrence of chronic interstitial 
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lung disease associated with SLE activity with 
variable response to treatment and outcome17.  Our 
patient showed excellent response to the pulsed 
monthly methylprednisolone and 
cyclophosphamide with clinical recovery and 
normalization of the   HRCT  scan  of the chest and 
the pulmonary function tests. In conclusion, 
unexplained dyspnea and tachycardia in SLE 
patients should be thoroughly investigated for early 
diagnosis and treatment and hence better outcome. 
 
CONSENT 
An informed consent was taken from the parents of 
the patient for publication of this case report and 
accompanying images.  
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